Özet, AhmetAtaergin, SelminArpacı, FikretKuzhan, OkanKömürcü, ŞerefÖztürk, BekirÖztürk, Mustafa2022-03-152022-03-152010Kanat, Ö. vd. (2010). "Modified outpatient dexamethazone, cytarabine and cisplatin regimen may lead to high response rates and low toxicity in Lymphoma". Medical Principles and Practice, 19(5), 344-347.1011-75711423-0151https://doi.org/10.1159/000316370https://pubmed.ncbi.nlm.nih.gov/20639655/http://hdl.handle.net/11452/25041Objective: Our purpose was to investigate the efficacy of and establish a toxicity profile for a modified regimen of dexamethasone, cytarabine and cisplatin (DHAP) for lymphoma outpatients. Subjects and Methods: Fifty-one lymphoma patients, 26 with Hodgkin's disease and 25 with non-Hodgkin's lymphoma, were included. The patients' median age was 32 years (range: 17-61). Twenty had progressive/refractory disease and 31 relapsed disease. Twenty-five were in clinical stage I/II and 26 in clinical stage III/IV before the initiation of salvage chemotherapy. DHAP consisted of dexamethasone (40 mg i.v. on days 1-4), cytarabine (2 g/m(2) i.v. as 3-hour infusion on days 2 in the evening and 3 in the morning) and cisplatin (35 mg/m(2) as 2-hour infusion on days 1-3) were administered every 21 days. A total of 154 cycles of modified DHAP were administered, with a median of 3 cycles per patient (range: 2-4). Results: The main toxicity was myelosuppression. WHO grade III-IV neutropenia and grade III-IV thrombocytopenia were observed in 27 (52.9%) and 21 (41%) patients, respectively. The overall response rate (85% for Hodgkin's disease and 95% for non-Hodgkin's lymphoma) was 88.3% (39.2% complete response and 49.1% partial response). Conclusion: The results showed that this outpatient schedule of DHAP was well tolerated and an effective salvage regimen.eninfo:eu-repo/semantics/openAccessDexamethasone, cytarabine and cisplatinNon-Hodgkin's lymphomaHodgkin's diseaseSalvage chemotherapyEffective salvage therapyDiseaseTransplantationCytoreductionChemotherapyIfosfamideEtoposideESHAPDHAPGeneral & internal medicineAdolescentAdultAntineoplastic combined chemotherapy protocolsCisplatinCytarabineDexamethasoneFemaleHodgkin diseaseHumansLymphoma, non-hodgkinMaleMiddle agedOutpatientsYoung adultArticle0002805193000042-s2.0-7795481363134434719520639655Medicine, general & internalLarge Cell Lymphoma; Burkitt Lymphoma; RituximabBleomycinCisplatinCyclophosphamideCytarabineDacarbazineDexamethasoneDoxorubicinFolinic acidMethotrexatePrednisoneVinblastineVincristineAntineoplastic agentCisplatinCytarabineDexamethasoneAdolescentAdultArticleBone marrow suppressionCancer combination chemotherapyCancer stagingDrug efficacyHodgkin diseaseHumanLymphomaMajor clinical studyMultiple cycle treatmentNephrotoxicityNeurotoxicityNeutropeniaNonhodgkin lymphomaOutpatient careThrombocytopeniaTreatment responseClinical trialFemaleLymphoma, non-hodgkinMaleMiddle agedOutpatientPhase 2 clinical trialYoung adult